Bailard Inc. Buys New Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Bailard Inc. purchased a new position in Protalix BioTherapeutics, Inc. (NYSE:PLX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 68,100 shares of the company’s stock, valued at approximately $121,000.

A number of other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in Protalix BioTherapeutics by 12.8% in the third quarter. Bank of New York Mellon Corp now owns 165,680 shares of the company’s stock valued at $275,000 after buying an additional 18,760 shares during the period. SG Americas Securities LLC bought a new position in shares of Protalix BioTherapeutics in the 3rd quarter worth about $50,000. Barclays PLC lifted its stake in shares of Protalix BioTherapeutics by 251.6% in the 3rd quarter. Barclays PLC now owns 46,511 shares of the company’s stock valued at $77,000 after purchasing an additional 33,281 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Protalix BioTherapeutics by 45.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 167,536 shares of the company’s stock valued at $278,000 after purchasing an additional 51,997 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Protalix BioTherapeutics during the third quarter worth approximately $229,000. 16.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com lowered Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 15th.

Protalix BioTherapeutics Stock Up 3.5 %

Shares of NYSE PLX opened at $1.19 on Tuesday. The firm has a market cap of $86.93 million, a PE ratio of 23.80 and a beta of 0.89. The company’s fifty day simple moving average is $1.32 and its 200 day simple moving average is $1.48. Protalix BioTherapeutics, Inc. has a 12-month low of $1.09 and a 12-month high of $3.55.

Protalix BioTherapeutics (NYSE:PLX) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.04). The company had revenue of $10.49 million for the quarter, compared to analyst estimates of $8.15 million. Protalix BioTherapeutics had a net margin of 12.69% and a return on equity of 29.73%. On average, equities analysts predict that Protalix BioTherapeutics, Inc. will post 0.14 earnings per share for the current year.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.